GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Search
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
biolabs-heidelberg
Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”